Pay in 4 interest-free payments of $6.16 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
In our survey, 31% to 36% of our cohorts have reported reduced alcohol consumption after starting a GLP-1 regime
This is a bit more expensive than the competition
For perimenopausal women, weight management becomes particularly challenging due to hormonal fluctuations that affect metabolism, appetite regulation, and body composition
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist designed to bind to GLP-1 receptors, which help regulate appetite.[4] Semaglutide was originally developed as a treatment for T2D to improve blood sugar levels, but clinical trials later showed that patients also lost weight while taking it.[4-8] Additional studies support semaglutides effectiveness in promoting weight loss in non-diabetics.[5,8,11] Semaglutide supports weight loss by suppressing appetite, delaying stomach emptying, and stimulating insulin secretion.[4] It is typically used alongside dietary changes and exercise in adults with and without diabetes.[4] All GLP-1 medications require a prescription from a healthcare provider
Trial Structure Duration: 48 weeks of treatment Participants: 338 adults randomized 2:1:1:1:1:2:2 to placebo or retatrutide groups Doses tested: 1mg, 4mg, 8mg, 12mg (all with slow titration from 2mg starting dose) Lifestyle intervention: All participants received counseling on diet (500 kcal/day deficit) and exercise (150 min/week) Primary endpoint: Percent weight change at 24 weeks Key secondary endpoints: Weight change at 48 weeks, proportion achieving 5%, 10%, 15% loss The trial used a slow titration protocol to minimize side effects: all groups except the 1mg dose started at 2mg weekly and escalated every 4 weeks
US$ 27.06
US$ 21.48
US$ 26.51
US$ 27.28
US$ 28.77
US$ 20.70
US$ 28.59
US$ 25.32
US$ 23.17
